{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:24:02Z","timestamp":1787171042494,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1185","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify predictors of relapse in oligometastatic prostate cancer patients treated with Stereotactic Ablative Radiotherapy (SABR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 57 patients with metachronous oligometastatic prostate cancer treated with SABR between January 2018 and December 2023. SABR was delivered with a median dose of 30\u2009Gy (range 24-36\u2009Gy) in 3-5 fractions. The primary endpoint was disease-free survival, while secondary endpoints included local relapse rates. Kaplan\u2013Meier survival estimation and Cox proportional hazards regression analyses were used to identify prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a median follow-up of 34.5\u2009months, the 1- and 2-year DFS rates were 64.5% and 24.3%, respectively. Local control was achieved in 87% of patients. Multivariate analysis revealed post-SABR PSA reduction as the only significant predictor of relapse (HR\u2009=\u20090.235, 95% CI, 0.085-0.644, P\u2009=\u2009.005), indicating a 76.5% lower risk of recurrence in patients demonstrating substantial PSA declines after treatment. Traditional prognostic markers, including Gleason score, initial PSA levels, prior hormone therapy, and metastatic site did not significantly correlate with relapse risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Post-SABR PSA kinetics are a more reliable predictor of relapse than conventional risk stratification factors in oligometastatic prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Advances in knowledge<\/jats:title>\n                    <jats:p>In this single-center cohort of metachronous oligometastatic prostate cancer treated with SABR (including both nodal and osseous metastases), early post-SABR PSA reduction was independently associated with relapse risk. These findings provide additional quantitative support for PSA dynamics as a pragmatic biomarker that may help stratify follow-up intensity and identify patients at higher likelihood of occult systemic disease, warranting prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjr\/tqag104","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:29:12Z","timestamp":1783085352000},"page":"1820-1826","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of relapse in oligometastatic prostate patients receiving stereotactic ablative radiotherapy"],"prefix":"10.1093","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-7139","authenticated-orcid":false,"given":"Saleh","family":"Sandoughdaran","sequence":"first","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veni","family":"Ezhil","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Mikropoulos","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Jane","family":"Conway","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Nanapragasam","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Reinlo","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Rickard","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Distefano","sequence":"additional","affiliation":[{"name":"Royal Surrey Cancer Centre, Royal Surrey County Hospital , Guildford GU2 7XX,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026081915313354900_tqag104-B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"2026081915313354900_tqag104-B2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"2026081915313354900_tqag104-B3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13014-023-02302-8","article-title":"Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer","volume":"18","author":"Mohan","year":"2023","journal-title":"Radiat Oncol"},{"key":"2026081915313354900_tqag104-B4","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/j.ijrobp.2018.06.367","article-title":"PSMA-directed biologically-guided radiation therapy of castration-sensitive oligometastatic prostate cancer patients","volume":"102","author":"Phillips","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026081915313354900_tqag104-B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euo.2022.09.007","article-title":"Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers","volume":"6","author":"Huynh","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"2026081915313354900_tqag104-B6","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026081915313354900_tqag104-B7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JU.0000000000002898","article-title":"Metastasis-directed therapy without androgen deprivation therapy in solitary oligorecurrent prostate cancer","volume":"208","author":"Andrews","year":"2022","journal-title":"J Urol"},{"key":"2026081915313354900_tqag104-B8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.ijrobp.2019.08.008","article-title":"Radiation therapy in the definitive management of oligometastatic prostate cancer: the Johns Hopkins experience","volume":"105","author":"Deek","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026081915313354900_tqag104-B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.radonc.2022.02.016","article-title":"Early PSA density kinetics predicts biochemical and local failure following extreme hypofractionated radiotherapy in intermediate-risk prostate cancer","volume":"169","author":"Greco","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026081915313354900_tqag104-B10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","article-title":"UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy","volume":"34","author":"Diez","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026081915313354900_tqag104-B11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026081915313354900_tqag104-B12","doi-asserted-by":"publisher","first-page":"oyaf154","DOI":"10.1093\/oncolo\/oyaf154","article-title":"Oligometastatic pancreatic cancer: current state of management and emerging therapies","volume":"30","author":"Khomiak","year":"2025","journal-title":"Oncologist"},{"key":"2026081915313354900_tqag104-B13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/jco.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase ii trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026081915313354900_tqag104-B14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026081915313354900_tqag104-B15","volume-title":"Evaluating the Immunological Effects of Stereotactic Ablative Radiotherapy in Patients with Primary and Oligometastatic Cancer","author":"Reed","year":"2024"},{"key":"2026081915313354900_tqag104-B16","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.adro.2020.10.016","article-title":"Markers of toxicity and response to radiation therapy in patients with prostate cancer","volume":"6","author":"Nasser","year":"2021","journal-title":"Adv Radiat Oncol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqag104\/68691250\/tqag104.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1185\/1820\/68691250\/tqag104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/99\/1185\/1820\/68691250\/tqag104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:31:39Z","timestamp":1787167899000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/99\/1185\/1820\/8724141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":16,"journal-issue":{"issue":"1185","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqag104","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,3]]}}}